The BRAF Kinase Inhibitors Market is driven by rising prevelance of cancer
The BRAF Kinase Inhibitors Market involves drugs that act as targeted therapy against cancers caused due to mutations in BRAF genes. BRAF kinase inhibitors work by blocking the BRAF proteins from working properly and inhibit tumor cell growth. Some key BRAF inhibitors include vemurafenib, dabrafenib and encorafenib. BRAF inhibitors are majorly used for treating melanoma skin cancer that has...
0 Comments
0 Shares